Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin superfamily member 9B (IGSF9B) is an evolutionarily conserved, brain‐specific cell adhesion molecule selectively localized to inhibitory synapses of GABAergic interneurons. It organizes distinct subsynaptic domains and interacts with synaptic organizers such as Neuroligin-2 through scaffolding molecules like S-SCAM/MAGI-2, supporting inhibitory synapse development and maintenance[1][2][3]. IGSF9B shows activity-dependent, cell type-specific expression in the brain and is involved in the regulation of inhibitory postsynaptic potential, synaptic transmission, and neural circuit plasticity. Genetic variants in IGSF9B have been associated with neuropsychiatric disorders including schizophrenia and major depression, as well as with neurodevelopmental circuit changes and anxiety behaviors in animal models. To date, IGSF9B is not a classical pharmacological target but remains of interest in neuroscience for understanding inhibitory synaptic architecture and brain disease mechanisms[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin superfamily member 9B (IGSF9B).